非小细胞肺癌个体化治疗：分子标志的现状和未来

尽管非小细胞肺癌（ＮＳＣＬＣ）的治疗已有较大的进展，但总体而言肺癌患者的预后仍然较差。个体化治疗能选择最有效的治疗策略使疗效最大化，最大程度降低毒性。对生物因子能否指导治疗决策的预测是个体化治疗的关键，最终将改善患者预后。基因组学和蛋白质组学研究针对ＮＳＣＬＣ患者的肿瘤组织进行分子检测，为每一个患者提供最有效的治疗。尽管在临床实践中，应用基因组学和蛋白质组学检测技术仍有很大的困难，但新技术的快速发展能克服这些障碍。

Individualized therapy in non-small cell lung cancer: future versus current clinical practice of biomarkers

Despite advances in the management of non-small cell lung cancer(NSCLC),improvements in survival are marginal and the overall prognosis for patients remains poor.Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity.The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes.Genomic and...